HC Wainwright & Co. Reiterates Neutral on HilleVax, Maintains $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Neutral rating on HilleVax (NASDAQ:HLVX) and maintained a $2 price target.
August 12, 2024 | 12:14 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Neutral rating on HilleVax and maintained a $2 price target.
The reiteration of a Neutral rating and maintenance of a $2 price target suggests no significant change in the analyst's outlook on HilleVax. This is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100